recording an average of over 7 days of heart monitoring. Despite US FDA approval, the Zio Patch has met slow acceptance possibly due to reimbursement hurdles. Explanations for the slow acceptance ...

Scripps Health physicians are studying the use of Zio Patch, a single-use ambulatory ... adhesive bandage and can continuously monitor a patient’s heart rhythm for up to 14 days.

The stock of iRhythm went from $30 to $285 over a similar stretch, as its Zio ECG-patch won most of the medical market for the long-term monitoring that determines if heart flutters actually are AFib.

Rhythm Technologies (Nasdaq:IRTC) announced that the FDA granted 510(k) clearance for Zio AT design modifications and ...

A heart monitor developed by iRhythm has become the first product to be endorsed by NICE in a pilot project covering digital health technologies. In new guidance, the health technology assessment ...

The Zio AI continuous monitoring system combines a wearable electrocardiogram (ECG) patch, named the Zio AT ... on both symptomatic and asymptomatic heart events, continuously recording ECG ...

Technologies announced that the results of the Extended Ambulatory ECG Monitoring Enhances Identification of Higher-Risk ...

clearance for the Zio AT cardiac monitoring device. This approval addresses past regulatory setbacks and covers design updates made to the system, including improvements to the wearable patch and ...

The Zio AT patch records continuous ECG data for up to 14 days and ... The U.S. Food and Drug Administration (FDA) granted 510(k) clearance for design updates to iRhythm's Zio AT heart monitoring ...